LONDON: AstraZeneca and Daiichi Sankyo said on Thursday their breast cancer treatment Enhertu has been approved for use in England’s state-run health care system, expanding access to a drug that has been available in Scotland since 2023. The companies said they will now seek approval for access from health bodies in Wales and Northern Ireland. The approval by the National Institute for Health and Care Excellence (NICE) clears a key hurdle to wider adoption in the UK after funding for Enh
AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England
Advertisement
Leaderboard ad — 728×90
Advertisement
In-article ad — fluid
This is a curated summary. The full report, with all details and context, is available from the original publisher.
Read the full story at Arab NewsHeadline, summary and image are © Arab News and are shown here under standard aggregation practice with full attribution. News Inspection does not claim ownership of this reporting.
